US 11,680,100 B2
B7-H3 antibody, antigen-binding fragment thereof and medical use thereof
Jinming Gu, Shanghai (CN); Xiaohua Wang, Shanghai (CN); Xin Ye, Shanghai (CN); Liuqing Yang, Shanghai (CN); Ting Zhang, Shanghai (CN); Weikang Tao, Shanghai (CN); and Lianshan Zhang, Shanghai (CN)
Assigned to Hansoh (Shanghai) Healthtech Co., Ltd., Shanghai (CN); and Changzhou Hansoh Pharmaceutical Co., Ltd., Changzhou (CN)
Filed by Hansoh (Shanghai) Healthtech Co., Ltd., Shanghai (CN); and Changzhou Hansoh Pharmaceutical Co., Ltd., Shanghai (CN)
Filed on Dec. 15, 2020, as Appl. No. 17/121,893.
Application 17/121,893 is a continuation of application No. 16/497,687, granted, now 10,899,837, previously published as PCT/CN2018/081249, filed on Mar. 30, 2018.
Claims priority of application No. 201710206261.2 (CN), filed on Mar. 31, 2017.
Prior Publication US 2021/0101984 A1, Apr. 8, 2021
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); G01N 33/577 (2006.01)
CPC C07K 16/2827 (2013.01) [G01N 33/577 (2013.01); C07K 2317/21 (2013.01); C07K 2317/92 (2013.01); G01N 2333/70532 (2013.01)] 17 Claims
 
1. A method for treating a cancer related to a B7-H3 positive cancer cell, wherein the method comprises administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a monoclonal anti-B7-H3 antibody or antigen-binding fragment thereof comprising:
(i) an antibody heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 10, 11 and 12, respectively; and an antibody light chain variable region comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 13, 14 and 15, respectively; or
(ii) an antibody heavy chain variable region comprising HCDR1, HCDR2, and HCDR3 having the amino acid sequences of SEQ ID NOs: 16, 17 and 18, respectively; and an antibody light chain variable region comprising LCDR1, LCDR2, and LCDR3 having the amino acid sequences of SEQ ID NOs: 19, 20 and 21, respectively.